Nabil E Boutagy1, Albert J Sinusas2,3. 1. Section of Cardiovascular Medicine, Department of Medicine, Yale University School of Medicine, 375 Congress Avenue, New Haven, CT, 06519, USA. 2. Section of Cardiovascular Medicine, Department of Medicine, Yale University School of Medicine, 375 Congress Avenue, New Haven, CT, 06519, USA. Albert.sinusas@yale.edu. 3. Department of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT, USA. Albert.sinusas@yale.edu.
Abstract
PURPOSE OF REVIEW: The purpose of this review was to summarize current advances in positron emission tomography (PET) cardiac autonomic nervous system (ANS) imaging, with a specific focus on clinical applications of novel and established tracers. RECENT FINDINGS: [11C]-Meta-hydroxyephedrine (HED) has provided useful information in evaluation of normal and pathological cardiovascular function. Recently, [11C]-HED PET imaging was able to predict lethal arrhythmias, sudden cardiac death (SCD), and all-cause mortality in heart failure patients with reduced ejection fraction (HFrEF). In addition, initial [11C]-HED PET imaging studies have shown the potential of this agent in elucidating the relationship between impaired cardiac sympathetic nervous system (SNS) innervation and the severity of diastolic dysfunction in HF patients with preserved ejection fraction (HFpEF) and in predicting the response to cardiac resynchronization therapy (CRT) in HFrEF patients. Longer half-life 18F-labeled presynaptic SNS tracers (e.g., [18F]-LMI1195) have been developed to facilitate clinical imaging, although no PET radiotracers that target the ANS have gained wide clinical use in the cardiovascular system. Although the use of parasympathetic nervous system radiotracers in cardiac imaging is limited, the novel tracer, [11C]-donepezil, has shown potential utility in initial studies. Many ANS radioligands have been synthesized for PET cardiac imaging, but to date, the most clinically relevant PET tracer has been [11C]-HED. Recent studies have shown the utility of [11C]-HED in relevant clinical issues, such as in the elusive clinical syndrome of HFpEF. Conversely, tracers that target cardiac PNS innervation have been used less clinically, but novel tracers show potential utility for future work. The future application of [11C]-HED and newly designed 18F-labeled tracers for targeting the ANS hold promise for the evaluation and management of a wide range of cardiovascular diseases, including the prognostication of patients with HFpEF.
PURPOSE OF REVIEW: The purpose of this review was to summarize current advances in positron emission tomography (PET) cardiac autonomic nervous system (ANS) imaging, with a specific focus on clinical applications of novel and established tracers. RECENT FINDINGS:[11C]-Meta-hydroxyephedrine (HED) has provided useful information in evaluation of normal and pathological cardiovascular function. Recently, [11C]-HED PET imaging was able to predict lethal arrhythmias, sudden cardiac death (SCD), and all-cause mortality in heart failurepatients with reduced ejection fraction (HFrEF). In addition, initial [11C]-HED PET imaging studies have shown the potential of this agent in elucidating the relationship between impaired cardiac sympathetic nervous system (SNS) innervation and the severity of diastolic dysfunction in HF patients with preserved ejection fraction (HFpEF) and in predicting the response to cardiac resynchronization therapy (CRT) in HFrEF patients. Longer half-life 18F-labeled presynaptic SNS tracers (e.g., [18F]-LMI1195) have been developed to facilitate clinical imaging, although no PET radiotracers that target the ANS have gained wide clinical use in the cardiovascular system. Although the use of parasympathetic nervous system radiotracers in cardiac imaging is limited, the novel tracer, [11C]-donepezil, has shown potential utility in initial studies. Many ANS radioligands have been synthesized for PET cardiac imaging, but to date, the most clinically relevant PET tracer has been [11C]-HED. Recent studies have shown the utility of [11C]-HED in relevant clinical issues, such as in the elusive clinical syndrome of HFpEF. Conversely, tracers that target cardiac PNS innervation have been used less clinically, but novel tracers show potential utility for future work. The future application of [11C]-HED and newly designed 18F-labeled tracers for targeting the ANS hold promise for the evaluation and management of a wide range of cardiovascular diseases, including the prognostication of patients with HFpEF.
Authors: P H Elsinga; P Doze; A van Waarde; R M Pieterman; P K Blanksma; A T Willemsen; W Vaalburg Journal: Eur J Pharmacol Date: 2001-12-21 Impact factor: 4.432
Authors: Caroline H Roney; Charles Sillett; John Whitaker; Jose Alonso Solis Lemus; Iain Sim; Irum Kotadia; Mark O'Neill; Steven E Williams; Steven A Niederer Journal: Eur Heart J Cardiovasc Imaging Date: 2021-12-18 Impact factor: 6.875
Authors: Jean Z Wang; Jason G E Zelt; Nicole Kaps; Aaryn Lavallee; Jennifer M Renaud; Benjamin Rotstein; Rob S B Beanlands; James A Fallavollita; John M Canty; Robert A deKemp Journal: J Nucl Cardiol Date: 2021-08-02 Impact factor: 5.952
Authors: Sara Roslin; Peter Brandt; Patrik Nordeman; Mats Larhed; Luke R Odell; Jonas Eriksson Journal: Molecules Date: 2017-10-10 Impact factor: 4.411
Authors: Tong Wang; Kai Yi Wu; Robert C Miner; Jennifer M Renaud; Rob S B Beanlands; Robert A deKemp Journal: EJNMMI Res Date: 2018-07-20 Impact factor: 3.138